EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages

S Jahanbakhsh, J Howland, M O Ndayishimiye Uwineza, M T Thwaites, C M Pillar, A W Serio, D M Anastasiou, D A Hufnagel

JAC-Antimicrobial Resistance · 04.09.2023 · 5 (5)

DOI: 10.1093/jacamr/dlad104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 15.09.2023. Verfasst von S Jahanbakhsh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, MI, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paratek Pharmaceuticals, Inc.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omadacycline is an aminomethylcycline antibiotic in the tetracycline class that was approved by the US FDA in 2018 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is available in both IV and oral formulations. Omadacycline has broad-spectrum in vitro activity and clinical efficacy against infections caused by Gram-positive and Gram-negative pathogens. Omadacycline is being evaluated in a 3 month placebo-controlled Phase 2 clinical trial of oral omadacycline versus placebo in adults with non-tuberculous mycobacteria (NTM) pulmonary disease caused by Mycobacterium abscessus (NCT04922554).

Objectives

To determine if omadacycline has intracellular antimicrobial activity against NTM, bacteria that can cause chronic lung disease, in an ex vivo model of intracellular infection.

Methods

Two strains of M. abscessus were used to infect THP-1 macrophages. Intracellular M. abscessus was then challenged with omadacycline and control antibiotics at multiples of the MIC over time to evaluate intracellular killing.

Results

At 16 × the MIC at 72 h, omadacycline treatment of intracellular NTM yielded a log10 reduction in cfu of 1.1 (91.74% reduction in cfu) and 1.6 (97.65% reduction in cfu) consistent with killing observed with tigecycline, whereas amikacin and clarithromycin at 16 × the MIC did not show any reduction in cfu against the intracellular M. abscessus.

Conclusions

Omadacycline displayed intracellular activity against M. abscessus within macrophages. The activity was similar to that of tigecycline; as expected, intracellular killing was not observed with clarithromycin and amikacin.

Autor:innen und Institutionen

  • Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, MI, USA.
  • Paratek Pharmaceuticals, Inc., King of Prussia, PA, USA.

Förderung

  • Paratek Pharmaceuticals, Inc

Zitieren

APA

Jahanbakhsh, S., Howland, J., Ndayishimiye Uwineza, M. O., Thwaites, M. T., Pillar, C. M., Serio, A. W., Anastasiou, D. M., & Hufnagel, D. A. (2023). Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages. JAC-Antimicrobial Resistance, 5(5). https://doi.org/10.1093/jacamr/dlad104

Vancouver

Jahanbakhsh S, Howland J, Ndayishimiye Uwineza MO, Thwaites MT, Pillar CM, Serio AW, et al. Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages. JAC-Antimicrobial Resistance. 2023;5(5). doi:10.1093/jacamr/dlad104

BibTeX
@article{Jahanbakhsh2023,
  author = {Jahanbakhsh, S and Howland, J and Ndayishimiye Uwineza, M O and Thwaites, M T and Pillar, C M and Serio, A W and Anastasiou, D M and Hufnagel, D A},
  title = {Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages},
  journal = {JAC-Antimicrobial Resistance},
  year = {2023},
  volume = {5},
  number = {5},
  doi = {10.1093/jacamr/dlad104}
}
Kostenlos starten →